AP
TEVA icon

Appleton Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Appleton Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,677
Closed -$288K – 251
2017
Q2 		$288K Sell
8,677
-510
-6% -$15.8K 0.05% 204
2017
Q1 		$295K Sell
9,187
-200
-2% -$6.83K 0.05% 196
2016
Q4 		$340K Sell
9,387
-2,290
-20% -$91.4K 0.07% 168
2016
Q3 		$537K Sell
11,677
-150
-1% -$7.83K 0.1% 149
2016
Q2 		$594K Sell
11,827
-451
-4% -$24K 0.12% 136
2016
Q1 		$657K Buy
12,278
+4,890
+66% +$287K 0.13% 125
2015
Q4 		$485K Buy
7,388
+285
+4% +$17.6K 0.1% 148
2015
Q3 		$401K Sell
7,103
-1,501
-17% -$97.3K 0.09% 149
2015
Q2 		$508K Buy
8,604
+100
+1% +$6.17K 0.11% 125
2015
Q1 		$530K Hold
8,504
– – 0.12% 125
2014
Q4 		$489K Sell
8,504
-280
-3% -$15.6K 0.11% 119
2014
Q3 		$472K Buy
8,784
+1,176
+15% +$62.3K 0.11% 119
2014
Q2 		$399K Hold
7,608
– – 0.09% 130
2014
Q1 		$402K Sell
7,608
-440
-5% -$20.3K 0.1% 125
2013
Q4 		$323K Sell
8,048
-350
-4% -$13.8K 0.08% 130
2013
Q3 		$317K Sell
8,398
-520
-6% -$20.3K 0.09% 127
2013
Q2 		$350K Buy
+8,918
New +$347K 0.1% 107

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Appleton Partners's TEVA Position: Q3 2017 in Review

Appleton Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 8,677 shares — an estimated $288K sold.

Appleton Partners first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $657K in Q1 2016. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Appleton Partners reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Appleton Partners sold 8,677 Teva Pharmaceuticals shares in Q3 2017, an estimated $288K.
  • Appleton Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Appleton Partners's Teva Pharmaceuticals position peaked at $657K in Q1 2016.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Appleton Partners's 13F filing for Q3 2017, filed 12 Oct 2017.